PAI-1 deficiency prevents ECM deposition and reduces airway inflammation and remodeling, as well as AHR.195,196 Therefore, focusing on PAI-1 antagonists can be a viable therapeutic strategy in asthma. This evidence concerns the gene SERPINE1 and asthma.